<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Obstetrics and Gynaecology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/62BD448E-C35F-4E65-A090-014918671BEC"><gtr:id>62BD448E-C35F-4E65-A090-014918671BEC</gtr:id><gtr:firstName>Francesco</gtr:firstName><gtr:surname>Colucci</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900101"><gtr:id>9B9AB3FC-B313-4DD4-ADDF-DF167F4C8BC8</gtr:id><gtr:title>Natural killer cell migration in pregnancy and immunosurveillance regulated by PI3K</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900101</gtr:grantReference><gtr:abstractText>A class of white blood cells specialised in sensing cancer cells and destroyomg them, known as natural killer cells, are generally found in the circulation and in blood vessels of various organs, including lymph glands, bone marrow, liver and lungs. Surprisingly, these killer cells specifically expand in the uterus during pregnancy, supplying growth factors that help to build up the placenta that feeds the growing fetus. How do these fascinating cells achieve such different functions? One deciding factor is the microenvironment they travel to, which provides cues for these cells to develop into killers or builders. We have found that the molecular switch PI3K guides killer cells in their circulation. When this molecular switch is inactivated by genetic or pharmacological means, killer cells do not traffic normally to tumours and to the uterus. Our research plan, structured in three sections, aims to: i) understand how PI3K regulates the transition of killer cells from within the blood into the tissue; (ii) explore the mechanisms of killer cell migration to the site of tumour growth and metastasis; iii) appreciate how PI3K contributes to the placenta-building function of killer cells and its consequences on healthy fetal growth.</gtr:abstractText><gtr:technicalSummary>Natural killer (NK) cells are lymphocytes that reside mostly in the vasculature of lymphoid and non-lymphoid organs, participating in reproductive success, regulation of immune responses and in immunological surveillance of cancer and infections. The functional versatility of NK cells is the result of subset heterogeneity and depends on appropriate location. Yet little is known about the factors governing NK cell trafficking and extravasation. This is historically due to the lack of appropriate tools, including those permitting in situ identification and in vivo tracking of NK cells. Both of these critical tools have now been developed and are available in our laboratory. The lipid enzymes of the phosphoinositide 3-kinase (PI3K) family regulate cell survival, growth, metabolism and motility, and we have highlighted unique roles played by the p110delta isoform of class 1A PI3K (p110d) in NK cell migration, differentiation, cytokine secretion and tumour rejection. Furthermore, we have completed the first analysis of the receptor repertoire expressed on mouse uterine NK cells and identified receptor-ligand interactions essential for NK cell mediated recognition of melanoma cells. We now wish to test the hypothesis that p110d regulates NK cell migration and we seek to better understand the mechanisms of NK cell extravasation and the downstream consequences on health and disease. The project is structured in three sections, that aim (I) to dissect the NK cell-autonomous mechanisms of extravasation regulated by p110d, (II) to explore the downstream consequences on immunosurveillance of melanoma and (III) to determine how PI3K contributes to the uterine NK cell repertoire and function during healthy placental development and fetal growth.</gtr:technicalSummary><gtr:fund><gtr:end>2014-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>480536</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>227598</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical PhD Fellowship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>205251/Z/16/Z</gtr:fundingRef><gtr:id>B9E59578-3DE1-4279-92B5-9D169AB0DA89</gtr:id><gtr:outcomeId>58b9424f238f20.04287413</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Centre for Trophoblast Research</gtr:department><gtr:description>Graduate Studentship</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>ACD9E3C4-F313-48C1-A3A7-E6EF7D2D4267</gtr:id><gtr:outcomeId>58b943a39e93b7.24652176</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Centre for Trophoblast Research</gtr:department><gtr:description>Graduate Studentships</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>F1E444E7-5CAA-4824-B816-A6158969F80D</gtr:id><gtr:outcomeId>545b7ea856e0f8.10210331</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MedImmune Cambridge</gtr:department><gtr:description>Graduate Studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>MedImmune</gtr:fundingOrg><gtr:id>37CD7FC8-330E-4E54-A610-3086353BFDAE</gtr:id><gtr:outcomeId>58b944453462e7.14842417</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Centre for Trophoblast Research</gtr:department><gtr:description>Graduate Studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>6504AF7A-8E0A-4948-A383-397404EAFBC8</gtr:id><gtr:outcomeId>58b943e69520b6.33330171</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>094073/Z/10/Z</gtr:fundingRef><gtr:id>2907AAF9-D707-4C51-9237-8D4D87098A2F</gtr:id><gtr:outcomeId>58b9415f20a468.26556618</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80336</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Programme Infection and Immunity</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EAAC631B-A85B-45C4-8359-C2A9D7B1AE5B</gtr:id><gtr:outcomeId>ne1DGYzrKyy</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>214610</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:fundingRef>13010</gtr:fundingRef><gtr:id>04B24C6D-14EB-443C-AFC4-5B1274484691</gtr:id><gtr:outcomeId>545b7ce3041883.11248466</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2140661</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigator Award</gtr:description><gtr:end>2021-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>200841/Z/16/Z</gtr:fundingRef><gtr:id>00937D44-9A53-4DDF-A793-BB09F5DE8569</gtr:id><gtr:outcomeId>58b940a6425b34.88017435</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>209000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Marie Curie Fellowship</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>8F70DDA6-1FB6-4718-9C9D-AC2E7328182F</gtr:id><gtr:outcomeId>Hi76eF7Zthk</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1471752</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>094073/Z/10/Z</gtr:fundingRef><gtr:id>52BE86BF-DDB1-4B83-818B-783578181461</gtr:id><gtr:outcomeId>BmToqnBTmgt</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A1AE6597-E1D2-454C-B383-469F377DF22D</gtr:id><gtr:title>Paternal MHC expression on mouse trophoblast affects uterine vascularization and fetal growth.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfde47ab28666a7caf2c9695975090cf"><gtr:id>dfde47ab28666a7caf2c9695975090cf</gtr:id><gtr:otherNames>Madeja Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_16437_27_21300875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEAA9E0C-28BE-446D-99A2-FF0D54C1CA0B</gtr:id><gtr:title>How does variability of immune system genes affect placentation?</gtr:title><gtr:parentPublicationTitle>Placenta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baa990e34423fce623db0afe90d21bf8"><gtr:id>baa990e34423fce623db0afe90d21bf8</gtr:id><gtr:otherNames>Colucci F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0143-4004</gtr:issn><gtr:outcomeId>pm_16437_27_21665273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBB08DBE-B58C-4EE2-8E76-95371B00324A</gtr:id><gtr:title>HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06434da49e10eb578dae4c4d99b1f39c"><gtr:id>06434da49e10eb578dae4c4d99b1f39c</gtr:id><gtr:otherNames>Sottile R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>56d022d8e09434.71439579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0882E6EB-777F-40C6-A073-7A03D7A475F5</gtr:id><gtr:title>DBA-lectin reactivity defines mouse uterine natural killer cell subsets with biased gene expression.</gtr:title><gtr:parentPublicationTitle>Biology of reproduction</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbfbba64e0bed5a5bd0e165199be7334"><gtr:id>bbfbba64e0bed5a5bd0e165199be7334</gtr:id><gtr:otherNames>Chen Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3363</gtr:issn><gtr:outcomeId>pm_16437_27_22875907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>584881D7-0DA3-423C-8DA8-E492C1BDF289</gtr:id><gtr:title>Guardian of the genome turns on genes that alert natural killer cells.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08566cf6ba91177d32e2e52ae20cccb5"><gtr:id>08566cf6ba91177d32e2e52ae20cccb5</gtr:id><gtr:otherNames>Doisne JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>pm_16437_27_22142860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34637417-D720-43C1-AA22-B91E2FC11AA8</gtr:id><gtr:title>Inositol phospholipid signaling and the biology of natural killer cells.</gtr:title><gtr:parentPublicationTitle>Journal of innate immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0a57a7dab1e204d4deb8a9f1c70ce02"><gtr:id>d0a57a7dab1e204d4deb8a9f1c70ce02</gtr:id><gtr:otherNames>Kerr WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1662-811X</gtr:issn><gtr:outcomeId>pm_16437_27_21422750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2975A3F-F667-4A02-9D95-48B21BB8BCD8</gtr:id><gtr:title>MHC-dependent inhibition of uterine NK cells impedes fetal growth and decidual vascular remodelling.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef71c3c0ee0c597a5362639ef89ec68b"><gtr:id>ef71c3c0ee0c597a5362639ef89ec68b</gtr:id><gtr:otherNames>Kieckbusch J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_540e168e168f7bcd6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1236EBEB-5151-4838-ADB4-46BD201A7975</gtr:id><gtr:title>Medawar and the immunological paradox of pregnancy: 60 years on.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baa990e34423fce623db0afe90d21bf8"><gtr:id>baa990e34423fce623db0afe90d21bf8</gtr:id><gtr:otherNames>Colucci F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>545b7a122b7ed7.60303190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0D4C0A1-7554-4DD6-A11B-56A99255A916</gtr:id><gtr:title>Composition, Development, and Function of Uterine Innate Lymphoid Cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08566cf6ba91177d32e2e52ae20cccb5"><gtr:id>08566cf6ba91177d32e2e52ae20cccb5</gtr:id><gtr:otherNames>Doisne JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56d022d784a608.17437860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77F42D11-F984-420A-9D95-0F369515E0ED</gtr:id><gtr:title>Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba5abf2e6abd6e165905580075255cb4"><gtr:id>ba5abf2e6abd6e165905580075255cb4</gtr:id><gtr:otherNames>Ali TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56d0281fc0ed45.27602069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84758F1B-E7F7-42D3-940F-754850BB8CDC</gtr:id><gtr:title>Maternal uterine natural killer cells nurture fetal growth: in medio stat virtus.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baa990e34423fce623db0afe90d21bf8"><gtr:id>baa990e34423fce623db0afe90d21bf8</gtr:id><gtr:otherNames>Colucci F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>56d022d85b2239.83590068</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE0A6EAB-E9B2-4AEC-AC24-16B2F1451528</gtr:id><gtr:title>Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b3bbe27015d9b0d2dedbe98dbf0e42a"><gtr:id>1b3bbe27015d9b0d2dedbe98dbf0e42a</gtr:id><gtr:otherNames>Ormiston ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_16437_27_22832786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E4D8E48-090E-4E51-B7CF-40630B62E4B0</gtr:id><gtr:title>Uterine NK cells: active regulators at the maternal-fetal interface.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c643e43542907a83d2106d4e8557683d"><gtr:id>c643e43542907a83d2106d4e8557683d</gtr:id><gtr:otherNames>Moffett A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>545b7a12036955.33070201</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900101</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>